Form 4: Regeneron EVP Marion McCourt Executes Stock Option and Sells Shares Under 10b5-1 Plan

Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, exercised stock options and sold shares of common stock on July 1, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, executed a transaction involving the company's common stock on July 1, 2024.
• McCourt exercised non-qualified stock options to acquire 1,137 shares at a price of $372.46 per share.
• Simultaneously, McCourt sold 1,137 shares of common stock at a price of $1,047.11 per share.
• These transactions were executed under a pre-arranged trading plan (Rule 10b5-1(c)) adopted on February 13, 2024.
• Following these transactions, McCourt directly owns 12,931 shares of Regeneron common stock and indirectly owns 174 shares through a 401(k) plan.
• McCourt also continues to hold options for 1,137 shares.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. The use of 10b5-1 plans allows insiders to sell shares over a period of time, avoiding concerns about trading on inside information. These transactions are closely watched by investors for insights into management's perspective on the company's value.

Comparison to Industry Standards

• Executive compensation packages, including stock options, are standard practice among pharmaceutical companies like Regeneron.
• Companies such as Amgen, Gilead Sciences, and AbbVie also utilize stock options as part of their executive compensation plans.
• The vesting schedules and exercise prices of these options are typically benchmarked against industry peers to attract and retain top talent.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• Shareholders may view insider transactions as a signal of management's confidence (or lack thereof) in the company, but the 10b5-1 plan mitigates this concern.

Key Dates